Detection of Herpes Simplex Virus DNA in Cutaneous Lesions of Erythema Multiforme

Brice, Sylvia L.; Krzemien, Donna; Weston, William L.; Huff, J. Clark

doi:10.1111/1523-1747.ep12277397

Cited by 178 publications

(79 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the site of infection, viral antigens are presented to CD4 + Th1 lymphocytes by antigen presenting cells such as dendritic cells and macrophages, which initiate viral clearance by secreting cytokines such as interferon gamma that recruit and activate macrophages and natural killer cells [13,14]. In HSV-associated erythema multiforme, herpes simplex antigens and DNA are frequently detected in skin lesions [15]. However, isolation of infective HSV is usually negative and pathology does not show cytopathogenic effects.…”

Section: Discussionmentioning

confidence: 99%

The effect of herpesvirus infection on the expression of cell adhesion molecules on cultured human dermal microvascular endothelial cells

Kim

Bang

Lee

et al. 2000

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The effect of herpesvirus infection on the expression of cell adhesion molecules on cultured human dermal microvascular endothelial cells

Kim

Bang

Lee

et al. 2000

Journal of Dermatological Science

View full text Add to dashboard Cite

“…The pathogenesis is controversial. Evidence of HSV protein (129,158,196), DNA (15,36,131,190), and RNA (129) in HAEM lesions has been obtained. However, live HSV has seldom been recovered in culture (131), and inclusions typical of lytic HSV replication are not seen.…”

Section: Potential Toxicities Of Vaccinesmentioning

confidence: 96%

Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research

2003

View full text Add to dashboard Cite

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) cause prevalent, chronic infections that have serious outcomes in some individuals. Neonatal herpes may occur when the infant traverses the cervix during maternal genital herpes. Genital herpes is a major risk factor for human immunodeficiency virus type 1 transmission. Considerable efforts have been made to design and test vaccines for HSV, focusing on genital infection with HSV-2. Several protein subunit vaccines based on HSV-2 envelope glycoproteins have reached advanced-phase clinical trials. These antigens were chosen because they are the targets of neutralizing-antibody responses and because they elicit cellular immunity. Encouraging results have been reported in studies of treatment of HSV-seronegative women with a vaccine consisting of truncated glycoprotein D of HSV-2 and a novel adjuvant. Because most sexual HSV transmission occurs during asymptomatic shedding, it is important to evaluate the impact of vaccination on HSV-2 infection, clinically apparent genital herpes, and HSV shedding among vaccine recipients who acquire infection. There are several other attractive formats, including subunit vaccines that target cellular immune responses, live attenuated virus strains, and mutant strains that undergo incomplete lytic replication. HSV vaccines have also been evaluated for the immunotherapy of established HSV infection

show abstract

“…HSV DNA has been detected using the polymerase chain reaction in the cutaneous lesions of EM patients with clinically non-HSVassociated disease emphasising the primary role of HSV reactivation in the initiation of EM signs and symptoms [Brice et al, 1989;Darregh et al, 1991]. However, it should be noted that not all episodes of EM are precipitated by HSV infection, and not all HSV infection precipitates EM in individual patients.…”

Section: Discussionmentioning

confidence: 99%